A temperature-programmed preparative-scale gas chromatograph.

G. Hunter,M. Veldhuis

DOI: https://doi.org/10.1016/S0021-9673(01)80861-X

IF: 4.601

Journal of Chromatography A

Abstract:

What problem does this paper attempt to address?

Ethical challenges for Health Technology Assessment (HTA) in the evolving evidence landscape

Pietro Refolo,Katherine Duthie,Björn Hofmann,Michal Stanak,Neil Bertelsen,Bart Bloemen,Rosella Di Bidino,Wija Oortwijn,Costanza Raimondi,Dario Sacchini,Gert Jan van der Wilt,Kenneth Bond

DOI: https://doi.org/10.1017/s0266462324000394

2024-11-06

International Journal of Technology Assessment in Health Care

Abstract:Since its inception, Health Technology Assessment (HTA) has typically determined the value of a technology by collecting information derived from randomized clinical trials (RCTs), in line with the principles of evidence-based medicine (EBM). However, data from RCTs did not constitute the sole source of information, as other types of evidence (such as primary qualitative research) have often been utilized. Recent advances in both generating and collecting other types of evidence are broadening the landscape of evidence, adding complexity to the discussion of "robustness of evidence." What are the consequences of these recent developments for the methodology and conduct of HTA, the HTA community, and its ethical commitments? The aim of this article is to explore some ethical challenges that are emerging in the current evolving evidence landscape, particularly changes in evidence generation and collection (e.g., diversification of data sources), and shifting standards of evidence in the field of HTA (e.g., increasing acceptability of evidence that is thought of as lower quality). Our conclusion is that deciding how to best maintain trustworthiness is common to all these issues.

public, environmental & occupational health,health care sciences & services,medical informatics
The Launch of International Journal of Biochemistry and Molecular Biology.

Jian-Ting Zhang,J. Turchi,Rakesh Kumar,W. Hong,G. Shaw,Dengshun Wang

2010-07-28

Abstract:With publication of this inaugural issue, we are pleased to announce the launching of the International Journal of Biochemistry and Molecular Biology (ISSN 2152-4114) with the enthusiastic support and participation of all editorial board members as well as fellow scientists in the life science community. International Journal of Biochemistry and Molecular Biology is a peer-reviewed and open access online journal with a mission to facilitate the rapid dissemination of novel discoveries and findings in biochemistry and molecular biology to the scientific community and to the public. The primary goal of this open access online journal is to publish original research findings in biochemistry and molecular biology as well as review articles and hypotheses. International Journal of Biochemistry and Molecular Biology will also keep all the traditional features of print journals such as continuous volume, issue, and page numbers. All manuscripts including reviews will be subjected to peer review and published online within 1 months of acceptance. With the explosion of information and rapid advancement of science and technology, traditional paper print publishing gradually becomes a limiting factor in dissemination of important discoveries and findings. Many equal quality studies could not be published due to limited print space despite adoption of simultaneous online publications by the traditional existing journals. International Journal of Biochemistry and Molecular Biology offers another venue of unlimited space for quick publication of these high quality studies. However, these advantages in publishing in International Journal of Biochemistry and Molecular Biology are not at the expense of the quality of the published work. All manuscripts submitted to the International Journal of Biochemistry and Molecular Biology will be subjected to rigorous peer review with the highest standard of academic excellence. With this successful launching of the International Journal of Biochemistry and Molecular Biology, we face enormous challenges from competition with many other established journals in biochemistry and molecular biology. Taking advantage of the rapidness of publication with unlimited space as well as the enthusiastic support of our editorial board members, we believe that we will be able to overcome these challenges and make International Journal of Biochemistry and Molecular Biology a successful story. In closing, we would like to thank all our editorial board members, colleagues, and contributing authors for their support and participation. We also welcome any suggestions to improve this journal which likely will be a continuous evolutionary process. We look forward to working with everyone to better serve the scientific community and the public in information dissemination.
Deliberative Appraisal Processes in Health Technology Assessment

Marina Richardson,Nicole Mittmann,David Kaunelis

DOI: https://doi.org/10.51731/cjht.2021.64

2021-05-06

Canadian Journal of Health Technologies

Abstract:Deliberation — the bringing together of individuals with multiple perspectives, experiences, and values to critically examine evidence, share reasons and rationales, and reach a decision on a course of action — occurs at all stages of the health technology assessment (HTA) process. The focus of this report is on deliberation at the committee appraisal stage of HTA. The objectives are to review and conceptualize the evidence and key considerations for deliberative processes at the committee appraisal stage of HTA and the available guidance for assessing the quality of the deliberative process at this stage. National and international practices for deliberative processes at the committee appraisal stage of HTA vary depending on contextual considerations (e.g., type of health technology and the medical condition being treated), the mandate of the HTA organization, health system and funding structures, and societal values. Each aspect of the deliberative appraisal process should be rooted in the values of the health system and be principled, clear, transparent, purposeful, and reasoned.
Ultrasonographic and computed tomographic features of renal sinus lymphoma

R. Ruchman,Hus‐Chong Yeh,H. Mitty,B. Cohen,Michael L. Greenberg,R. Plous,David S. Mendelson

DOI: https://doi.org/10.1002/jcu.1870160107

1988-01-01

Journal of Clinical Ultrasound

Abstract:The involvement of the kidney by lymphoma is not an uncommon occurrence. Usual manifestations are either diffuse infiltration of the renal parenchyma or focal tumor formation. Diffuse infiltration of the renal sinus and periureteral fat, however, is rarely observed. The ultrasonographic features in this event are unique. We wish to report two such cases
A genuine need or nice to have? Understanding HTA representatives' perspectives on the use of patient preference data

Evi Germeni,Simon Fifer,Mickaël Hiligsmann,Barry Stein,Mandy Tonkinson,Maya Joshi,Alissa Hanna,Barry Liden,Deborah A. Marshall

DOI: https://doi.org/10.1017/s026646232400463x

2024-11-27

International Journal of Technology Assessment in Health Care

Abstract:Objectives The roles and potential value of patient preference (PP) data in health technology assessment (HTA) remain to be fully realized despite an expanding literature and various efforts to establish their utility. This article reports lessons learned through a series of collaborative workshops with HTA representatives, organized by the Health Technology Assessment International's Patient Preferences Project Subcommittee. Methods Five online workshops were conducted between June 2022 and June 2023, seeking to facilitate collaborative learning and reflection on ways that PP data can be integrated into HTA. Participants included nine HTA representatives from the United States, Canada, Australia, England, and the Netherlands. Workshops were recorded, transcribed, and thematically analyzed. Results Despite appreciating the value of PP data, participants were ambivalent about their use in HTA. Some felt that they were already getting the information they needed from the cost-effectiveness analysis or existing patient involvement processes. Others thought that PP data would be very helpful at the initial and final stage of the decision-making process and, particularly, in the following cases: (a) when technology has important non-health benefits; (b) when the clinical and/or cost-effectiveness evidence is marginal; and (c) when treatment is indicated for a large and heterogeneous population. Issues related to the validity and reliability of PP studies were frequently raised, with preference heterogeneity at the core of these concerns. Conclusions Collaborating with HTA representatives in the "co-creation" of PP research can help address their concerns and facilitate mutual learning about how PP data can be used in HTA.

public, environmental & occupational health,health care sciences & services,medical informatics
Pupil stabilization for SPHERE's extreme AO and high performance coronagraph system.

G. Montagnier,T. Fusco,J. Beuzit,D. Mouillet,J. Charton,L. Jocou

DOI: https://doi.org/10.1364/OE.15.015293

IF: 3.8

2007-11-08

Optics Express

Abstract:We propose a new concept of pupil motion sensor for astronomical adaptive optics systems and present experimental results obtained during the first laboratory validation of this concept. Pupil motion is an important issue in the case of extreme adaptive optics, high contrast systems, such as the proposed Planet Finder instruments for the ESO and Gemini 8-meter telescopes. Such high contrast imaging instruments will definitively require pupil stabilization to minimize the effect of quasi-static aberrations. The concept for pupil stabilization we propose uses the flux information from the AO system wave-front sensor to drive in closed loop a pupil tip-tilt mirror located in a focal plane. A laboratory experiment validates this concept and demonstrates its interest for high contrast imaging instrument.
Health technology assessment (HTA) and economic evaluation: efficiency or fairness first

Jeff Richardson,Michael Schlander

DOI: https://doi.org/10.1080/20016689.2018.1557981

2018-12-20

Abstract:The economic evaluation which supports Health Technology Assessment (HTA) should inform policy makers of the value to society conferred by a given allocation of resources. However, neither the theory nor practise of economic evaluation satisfactorily reflect social values. Both are primarily concerned with efficiency, commonly conceptualised as the maximisation of utility or quality adjusted life years (QALYs). The focus is upon the service and the benefits obtained from it. This has resulted in an evaluation methodology which discriminates against groups and treatments which the population would like to prioritise. This includes high cost treatments for patients with rare diseases. In contrast with prevailing methods, there is increasing evidence that the public would prefer a fairness-focused framework in which the service was removed from centre stage and replaced by the patient. However methods for achieving fairness are ad hoc and under-developed. The article initially reviews the theory of economic evaluation and argues that its focus upon individual utility and efficiency as defined by the theory omits potentially important social values. Some empirical evidence relating to population values is presented and four studies by the first author are reviewed. These indicate that when people adopt the social perspective of a citizen they have a preference for sharing the health budget in a way which does not exclude patients who require services that are not cost effective, such as orphan medicinal products (OMP's) and treatments for patients with ultra-rare diseases (URD's).
Challenges of Health Technology Assessment in Pluralistic Healthcare Systems: An ISPOR Council Report

Michael F. Drummond,Federico Augustovski,Devarshi Bhattacharyya,Jonathan Campbell,Nathorn Chaiyakanapruk,Yingyao Chen,Rosa Maria Galindo-Suarez,John Guerino,Aurelio Mejia,Michelle Mujoomdar,Daniel Ollendorf,Naoko Ronquest,Aleksandra Torbica,Emily Tsiao,John Watkins,Kai Yeung

DOI: https://doi.org/10.1016/j.jval.2022.02.006

IF: 5.156

2022-01-01

Value in Health

Abstract:Health technology assessment (HTA) has been growing in use over the past 40 years, especially in its impact on decisions regarding the reimbursement, adoption, and use of new drugs, devices, and procedures. In countries or jurisdictions with "pluralistic" healthcare systems, there are multiple payers or sectors, each of which could potentially benefit from HTA. Nevertheless, a single HTA, conducted centrally, may not meet the needs of these different actors, who may have different budgets, current standards of care, populations to serve, or decision-making processes.This article reports on the research conducted by an ISPOR Health Technology Assessment Council Working Group established to examine the specific challenges of conducting and using HTA in countries with pluralistic healthcare systems. The Group used its own knowledge and expertise, supplemented by a narrative literature review and survey of US payers, to identify existing challenges and any initiatives taken to address them. We recommend that countries with pluralistic healthcare systems establish a national focus for HTA, develop a uniform set of HTA methods guidelines, ensure that HTAs are produced in a timely fashion, facilitate the use of HTA in the local setting, and develop a framework to encourage transparency in HTA. These efforts can be enhanced by the development of good practice guidance from ISPOR or similar groups and increased training to facilitate local use of HTA.
Gender, Ethnicity, and Their Intersectionality in the Prediction of Smoking Outcome Expectancies in Regular Cigarette Smokers

C. Aguirre,Mariel S. Bello,Nafeesa Andrabi,Raina D. Pang,P. Hendricks,R. Bluthenthal,A. Leventhal

DOI: https://doi.org/10.1177/0145445515608146

2016-01-01

Behavior Modification

Abstract:The current study utilized the intersectionality framework to explore whether smoking outcome expectancies (i.e., cognitions about the anticipated effects of smoking) were predicted by gender and ethnicity, and the gender-by-ethnicity interaction. In a cross-sectional design, daily smokers from the general community (32.2% women; non-Hispanic African American [n = 175], non-Hispanic White [n = 109], or Hispanic [n = 26]) completed self-report measures on smoking expectancies and other co-factors. Results showed that women reported greater negative reinforcement (i.e., anticipated smoking-induced negative affect reduction) and weight control (i.e., anticipated smoking-induced appetite/weight suppression) expectancies than men. Hispanic (vs. African American or White) smokers endorsed greater negative reinforcement expectancies. A gender-by-ethnicity interaction was found for weight control expectancies, such that White women reported greater weight control expectancies than White men, but no gender differences among African American and Hispanic smokers were found. These findings suggest that gender, ethnicity, and their intersectionality should be considered in research on cognitive mechanisms that may contribute to tobacco-related health disparities.
Institute for Clinical and Economic Review – Peterson Health Technology Institute value assessment framework for digital health technologies

Steven D Pearson,Prabhjot Singh,Francesca Beaudoin,Jon Campbell,Lindsey Schapiro,Sarah K Emond,Caroline Pearson

DOI: https://doi.org/10.57264/cer-2023-0154

2023-12-01

Journal of Comparative Effectiveness Research

Abstract:Digital health technologies (DHTs) are a broad and rapidly innovating class of interventions with distinctive pathways for development, regulatory approval, uptake and reimbursement. Given the unique nature of DHTs, existing value assessment frameworks and evidence standards for health technologies such as drugs and devices are not directly applicable. The value assessment framework presented here describes a conceptual model and associated methods to guide assessments of DHTs. The framework seeks to accomplish two goals: to set evidence standards that guide technology developers to generate robust evidence on their products; and to provide reviews that help organizations adopt high-impact DHTs with the strongest evidence for delivering improved clinical outcomes and cost savings. This assessment framework will serve as the roadmap for future evaluations of DHTs by the Institute for Clinical and Economic Review (ICER) and the Peterson Health Technology Institute (PHTI). We believe that all stakeholders will benefit from comprehensive and explicit standards of evidence on the different dimensions necessary to understand the value of DHTs.

health care sciences & services
The political economy of the assessment of value of new health technologies

Jonathan Karnon,Laura Edney,Hossein Afzali

DOI: https://doi.org/10.1177/1355819617751816

2018-01-10

Abstract:Health technology assessment provides a common framework for evaluating the costs and benefits of new health technologies to inform decisions on the public funding of new pharmaceuticals and other health technologies. In Australia and England, empirical analyses of the opportunity costs of government spending on new health technologies suggest more quality adjusted life years are being forgone than are being gained by a non-trivial proportion of funded health technologies. This essay considers the relevance of available empirical estimates of opportunity costs and explores the relationship between the public funding of health technologies and broader political and economic factors. We conclude that the benefits of a general reduction in the prices paid by governments for new technologies outweigh the costs, but evidence of informed public acceptance of reduced access to new health technologies may be required to shift the current approach to assessing the value of new health technologies.

health policy & services
Algorithms and heuristics of health technology assessments: A retrospective analysis of factors associated with HTA outcomes for new drugs across seven OECD countries

Panos Kanavos,Erica Visintin,Arianna Gentilini

DOI: https://doi.org/10.1016/j.socscimed.2023.116045

Abstract:Context: Positive health technology assessment (HTA) outcomes can have important implications for equity, efficiency and timely patient access to novel therapies. Several outcomes and dimensions of benefit beyond utility feed into HTA processes. Objective: We analyse a proprietary dataset of HTA outcomes in 7 countries, to (a) test whether HTA decision-making is grounded in welfarist or extra-welfarist approaches; and (b) empirically determine the factors associated with positive HTA outcomes, the time to achieve these and establish the magnitude of inter-country differences in assessment processes. Methods: Data were extracted from publicly available HTA reports on drugs that received marketing authorisation between 2009 and 2018 (N = 1415). The outcomes of interest were the probability of positive HTA outcomes and the time-to-HTA outcome; these were examined with respect to clinical, regulatory, product- and disease-related, evidence uncertainty and contextual variables. Econometric models utilising survival analysis and multinomial logistic regression were specified. Findings: Positive HTA outcomes accounted for 87.3% of the sample (n = 1235), of which 71% (n = 1004) were restricted. Drugs with positive HTA outcomes were subject to clinical restrictions (n = 652, 46%), financial risk-sharing (n = 439, 31%) or had been rejected at least once (n = 282, 20%). Significant predictors of positive HTA outcomes were orphan drugs with cancer indications, high quality of evidence linked to clinical and economic evidence uncertainties which had been overcome, and contextual considerations, particularly innovativeness and unmet need. Comparative analyses revealed systematic differences between countries in their propensity to accept the same drugs, particularly oncology and orphan drugs. Conclusions: Our results are contextual and reinforce arguments in favour of explicitly accounting for social value judgements, establishing separate assessment frameworks for highly uncertain products, adopting risk mitigation strategies for novel therapies with early phase evidence, and sharing of HTA practices across settings. Lastly, HTA agencies have adopted an extra-welfarist approach to value assessment and resource allocation.
The Early Experiences of Ileorectal Anastomosis

R. Corbett,M. Chir

DOI: https://doi.org/10.1177/00359157590520S110

1959-01-01

Proceedings of the Royal Society of Medicine

Abstract:Following operation she did well for five days, after which she began to complain of lower Abdominal pain, although the ileostomy continued to work well. These symptoms continued and were accompanied by a rising pulse-rate which finally reached 110, and a temperature of 10060 6 F. On the ninth post-operative day, severe left upper quadrant pain occurred with tenderness and spasticity. The wound opened slightly and a musty odor was detected. Immediate operation was performed and a gas gangrene infection was found with some necrosis of the rectus muscle, but with intact peritoneum. The wound was opened widely, necrotic tissue debrided, and Dakin's tubes laid into the two sides of the wound through which a continuous wet dressing of hydrogen peroxide was maintained. Large doses of penicillin were administered intravenously. The patient slowly recovered and is now healthy and happy, with wounds healed and ileostomy functioning perfectly. BIBLIOGRAPHY 1 BANKS, B. M., KORELITZ, B. I., and ZETZEL, L. (1957) Gastroenterology, 32, 983. 2 BARGEN, J. A., JACKMAN, R. J., and KERR, J. G. (1938) Ann. intern. Med., 12, 399. 3 CATTELL, R. B. (1953) Amer. J. Surg., 86, 613. 4 CROHN, B. B., GARLOCK, J. H., and YARNIS, H. (1947) J. Amer. med. Ass., 134, 334. 5 DUKES, C. E. (1954) Ann. R. Coll. Surg. Engl., 14, 389. 6 RIPSTEIN, C. B. (1953)J. Amer. med. Ass., 152, 1093. 7 SCARBOROUGH, R. A. (1955) Amer. J. Surg., 89, 1224. 8 WARREN, S. (1957) Gastroenterology, 83, 399. 9 , and SOMMERS, S. C. (1954) J. Amer. med. Ass., 154,189.
Designing collaborations involving health technology assessment: discussions and recommendations from the 2024 health technology assessment international global policy forum

Rebecca Trowman,Antonio Migliore,Daniel A. Ollendorf

DOI: https://doi.org/10.1017/s0266462324000436

2024-11-06

International Journal of Technology Assessment in Health Care

Abstract:Although collaboration is an intensive way of working together, it is essential for such efforts to achieve shared goals. Health technology assessment (HTA) is transdisciplinary and has an important history of collaboration, with collaboration featuring increasingly in the strategic plans of HTA bodies and stakeholders. Collaboration can be between HTA bodies and between HTA bodies and other stakeholders—most notably regulators but increasingly payers, patient and caregiver organizations, clinicians–clinical societies, and academia. The 2024 HTAi Global Policy Forum (GPF) discussed collaborations involving HTA bodies, reviewing existing and previous collaborations to see what has worked and what can be learned. Core discussion themes included: (i) determining the collaboration purpose is essential but may be dynamic, changing over time; (ii) choosing the collaboration topic takes time, requiring upfront investment and stakeholder mapping; (iii) inviting the right participants and treating them equally is important, including those who can impact HTA, those who will be impacted by HTA and those who bring new information; (iv) collaborations need clear governance, defined roles, responsibilities, metrics, and case study–pilots can be a useful operational model; (v) resourcing collaborations sustainably is a challenge—the time, people, and money required are often under-estimated; (vi) undertaking continual, iterative learning reviews ensures ongoing value and impact of collaborations. Recommendations for future work include the development of a "go/no-go" checklist to determine when collaboration is needed, supplemented with a set of "best practice" principles for establishing and working in collaborations involving HTA bodies.

public, environmental & occupational health,health care sciences & services,medical informatics
Properdin: preparation from plasma fraction I of the Cohn method.

D. Spicer,L. Priester,E. V. Smith,B. E. Sanders

DOI: https://doi.org/10.1016/s0021-9258(18)70186-5

IF: 5.485

1959-04-01

Journal of Biological Chemistry

Abstract:
Incorporating public and wider stakeholder views in the design of health state valuation studies in adults and young people: an undervalued resource?

Philip A. Powell

DOI: https://doi.org/10.1080/14737167.2024.2334349

2024-03-26

Expert Review of Pharmacoeconomics & Outcomes Research

Abstract:KEYWORDS: Health state valuation (e.g. calculating numerical values representing people's relative preference for living in particular health states) is an essential ingredient for health technology assessment (HTA). It allows for the generation of utilities to calculate health-related quality of life outcomes and adds the 'QA' to the QALY, or quality-adjusted life year [ Citation 1 ]. For HTA, valuing health states uses standardized methodologies, such as time trade-off (TTO) or discrete choice experiment (DCE) with duration, with a targeted sample of people to derive their preference (or utility) weights for living in particular states of health relative to preference for survival or life expectancy. The sample used for valuing health states differs depending on locality and HTA body, but in the UK a sample of the adult (taxpaying) public is recruited, representative on key demographic criteria, such as age, sex, ethnicity, and socioeconomic status [ Citation 2 ].

pharmacology & pharmacy,health care sciences & services,health policy & services
Health technology assessment framework for artificial intelligence-based technologies

Rossella Di Bidino,Signe Daugbjerg,Sara C. Papavero,Ira H. Haraldsen,Americo Cicchetti,Dario Sacchini

DOI: https://doi.org/10.1017/s0266462324000308

2024-11-27

International Journal of Technology Assessment in Health Care

Abstract:Objectives Artificial intelligence (AI)-based health technologies (AIHTs) have already been applied in clinical practice. However, there is currently no standardized framework for evaluating them based on the principles of health technology assessment (HTA). Methods A two-round Delphi survey was distributed to a panel of experts to determine the significance of incorporating topics outlined in the EUnetHTA Core Model and twenty additional ones identified through literature reviews. Each panelist assigned scores to each topic. Topics were categorized as critical to include (scores 7–9), important but not critical (scores 4–6), and not important (scores 1–3). A 70 percent cutoff was used to determine high agreement. Results Our panel of 46 experts indicated that 48 out of the 65 proposed topics are critical and should be included in an HTA framework for AIHTs. Among the ten most crucial topics, the following emerged: accuracy of the AI model (97.78 percent), patient safety (95.65 percent), benefit–harm balance evaluated from an ethical standpoint (95.56 percent), and bias in data (91.30 percent). Importantly, our findings highlight that the Core Model is insufficient in capturing all relevant topics for AI-based technologies, as 14 out of the additional 20 topics were identified as crucial. Conclusion It is imperative to determine the level of agreement on AI-relevant HTA topics to establish a robust assessment framework. This framework will play a foundational role in evaluating AI tools for the early diagnosis of dementia, which is the focus of the European project AI-Mind currently being developed.

public, environmental & occupational health,health care sciences & services,medical informatics
Methodological Frameworks and Dimensions to Be Taken Into Consideration in Digital Health Technology Assessment: Protocol for a Scoping Review

Joan Segur-Ferrer,Carolina Moltó-Puigmartí,Roland Pastells-Peiró,Rosa Maria Vivanco-Hidalgo

DOI: https://doi.org/10.2196/39905

2022-10-12

JMIR Research Protocols

Abstract:Background: Health technology assessment (HTA) is one of the main tools that health systems have to appraise evidence and determine the value of a given health technology. Although the existing HTA frameworks are useful tools for the evaluation of a wide range of health technologies, more and more experts, organizations across the world, and HTA agencies are highlighting the need to update or develop specific methodological frameworks for the evaluation of digital health technologies in order to take into account additional domains that cover these technologies' intrinsic characteristics. Objective: The purpose of our scoping review is to identify the methodological frameworks that are used worldwide for the assessment of digital health technologies; determine what dimensions and aspects are being considered; and generate, through a thematic analysis, a proposal for a methodological framework that is based on the most frequently described dimensions in the literature. Methods: The scoping review will be performed in accordance with the guidelines established in the updated statement of the PRISMA-ScR (Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews). We will search for peer-reviewed and grey literature published between 2011 and the date of the search execution. The retrieved references will be reviewed in a single-blind manner by 2 independent authors, and their quality will be assessed by using the Critical Appraisal Skills Program tool. The ATLAS.ti software (Scientific Software Development GmbH) will be used for data extraction and to perform the thematic analysis. Results: The scoping review is currently (May 2022) in progress. It is expected to be completed in October 2022, and the final results of the research will be presented and published by November 2022. Conclusions: To our knowledge, no studies have been published to date that identify the existing methodological frameworks for digital HTA, determine which dimensions must be evaluated for correct decision-making, and serve as a basis for the development of a methodological framework of reference that health care systems can use to carry out this kind of assessment. This work is intended to address this knowledge gap of key relevance for the field of HTA.
Optimizing medical management of patients with pre-end-stage renal disease.

J. Pennell

DOI: https://doi.org/10.1016/S0002-9343(01)00891-9

2001-11-01

Abstract:

A temperature-programmed preparative-scale gas chromatograph.

Ethical challenges for Health Technology Assessment (HTA) in the evolving evidence landscape

The Launch of International Journal of Biochemistry and Molecular Biology.

Deliberative Appraisal Processes in Health Technology Assessment

Ultrasonographic and computed tomographic features of renal sinus lymphoma

A genuine need or nice to have? Understanding HTA representatives' perspectives on the use of patient preference data

Pupil stabilization for SPHERE's extreme AO and high performance coronagraph system.

Health technology assessment (HTA) and economic evaluation: efficiency or fairness first

Challenges of Health Technology Assessment in Pluralistic Healthcare Systems: An ISPOR Council Report

Gender, Ethnicity, and Their Intersectionality in the Prediction of Smoking Outcome Expectancies in Regular Cigarette Smokers

Institute for Clinical and Economic Review – Peterson Health Technology Institute value assessment framework for digital health technologies

The political economy of the assessment of value of new health technologies

Algorithms and heuristics of health technology assessments: A retrospective analysis of factors associated with HTA outcomes for new drugs across seven OECD countries

The Early Experiences of Ileorectal Anastomosis

Designing collaborations involving health technology assessment: discussions and recommendations from the 2024 health technology assessment international global policy forum

Properdin: preparation from plasma fraction I of the Cohn method.

Incorporating public and wider stakeholder views in the design of health state valuation studies in adults and young people: an undervalued resource?

Health technology assessment framework for artificial intelligence-based technologies

Methodological Frameworks and Dimensions to Be Taken Into Consideration in Digital Health Technology Assessment: Protocol for a Scoping Review

Optimizing medical management of patients with pre-end-stage renal disease.